{"disease":{"id":"familial-hypercholesterolemia-homozygous","name":"Familial hypercholesterolemia - homozygous","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"atorvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"lomitapide","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Juxtapid","generic_name":"LOMITAPIDE","company_name":"Chiesi","drug_phase":"marketed","molecular_target":"Microsomal triglyceride transfer protein large subunit","drug_class":"Microsomal Triglyceride Transfer Protein Inhibitor","quality_score":60,"revenue":"126","mechanism":"Juxtapid works by blocking the protein that helps transport cholesterol into the bloodstream."},{"drug_id":"ezetimibe","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"ezetrol","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"simvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"rosuvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"mipomersen","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kynamro","generic_name":"MIPOMERSEN","company_name":"Kastle Theraps Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Antisense Oligonucleotide","quality_score":24,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03814187","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03110432","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT04370899","title":"Early Detection of Familial Hypercholesterolemia in Children","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT07470723","title":"The ORIGIN-FH Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT04659863","title":"Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06597006","title":"Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02173158","title":"Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Aegerion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04948008","title":"Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":8,"lead_sponsor_name":"Shenzhen People's Hospital","has_results":false}],"total":8},"guidelines":[{"drug_id":"atorvastatin","guideline_body":"FDA label","recommendation":"As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).","line_of_therapy":"adj","evidence_grade":"1A","guideline_year":null},{"drug_id":"rosuvastatin","guideline_body":"FDA label","recommendation":"As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).","line_of_therapy":"adj","evidence_grade":"not specified","guideline_year":null},{"drug_id":"lipitor","guideline_body":"FDA label","recommendation":"As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).","line_of_therapy":"adj","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}